全文获取类型
收费全文 | 1836篇 |
免费 | 166篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 130篇 |
妇产科学 | 22篇 |
基础医学 | 183篇 |
口腔科学 | 53篇 |
临床医学 | 274篇 |
内科学 | 359篇 |
皮肤病学 | 18篇 |
神经病学 | 58篇 |
特种医学 | 223篇 |
外科学 | 273篇 |
综合类 | 46篇 |
一般理论 | 2篇 |
预防医学 | 140篇 |
眼科学 | 49篇 |
药学 | 99篇 |
1篇 | |
中国医学 | 2篇 |
肿瘤学 | 80篇 |
出版年
2021年 | 11篇 |
2019年 | 16篇 |
2018年 | 23篇 |
2017年 | 28篇 |
2016年 | 18篇 |
2015年 | 34篇 |
2014年 | 42篇 |
2013年 | 51篇 |
2012年 | 50篇 |
2011年 | 47篇 |
2010年 | 55篇 |
2009年 | 60篇 |
2008年 | 55篇 |
2007年 | 26篇 |
2006年 | 43篇 |
2005年 | 38篇 |
2004年 | 38篇 |
2003年 | 34篇 |
2002年 | 50篇 |
2001年 | 33篇 |
2000年 | 28篇 |
1999年 | 46篇 |
1998年 | 99篇 |
1997年 | 99篇 |
1996年 | 102篇 |
1995年 | 66篇 |
1994年 | 64篇 |
1993年 | 55篇 |
1992年 | 61篇 |
1991年 | 52篇 |
1990年 | 24篇 |
1989年 | 49篇 |
1988年 | 39篇 |
1987年 | 56篇 |
1986年 | 38篇 |
1985年 | 47篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 18篇 |
1981年 | 22篇 |
1980年 | 17篇 |
1979年 | 16篇 |
1978年 | 19篇 |
1977年 | 20篇 |
1976年 | 20篇 |
1975年 | 16篇 |
1973年 | 12篇 |
1972年 | 13篇 |
1969年 | 10篇 |
1966年 | 11篇 |
排序方式: 共有2013条查询结果,搜索用时 15 毫秒
1.
PJ Commerford 《Cardiovascular journal of Africa》2015,26(4):151-Aug;26(4):151
2.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献
3.
Hans Bosma Martin PJ van Boxtel Gertrudis IJM Kempen Jacques ThM van Eijk Jelle Jolles 《BMC public health》2007,7(1):179
Background
The aims of this study were to examine the extent to which higher intellectual abilities protect higher socio-economic groups from functional decline and to examine whether the contribution of intellectual abilities is independent of childhood deprivation and low birth weight and other socio-economic and developmental factors in early life. 相似文献4.
5.
6.
7.
In 1987, die Department of Health in the UK set up a working party to identify reasons contributing to a shortfall in donor organs. One recommendation was reimbursement to the District Health Authorities for costs incurred in providing the donor organs. The figure chosen was not to be seen as an incentive to donate organs, merely as an appropriate compensation for the costs incurred. There would be no direct payment to doctors, trustees or relatives of the donor. With the development of the competitive health care environment in the United Kingdom, the reimbursement of donating hospital costs is being considered with these data. 相似文献
8.
Previous reports in the literature have described correlation of increasing repeat length with severity of the phenotype, in Kennedy syndrome. We describe male siblings with different repeat lengths, with lack of expression of the phenotype in the sibling with the longer repeat length. The phenotype was identical to motor neurone disease. There is variability of expression in Kennedy syndrome and repeat length even in siblings cannot be taken as a conclusive indicator of severity. CAG repeat length cannot be used to predict the natural history of Kennedy disease. The diagnosis of Kennedy syndrome should be considered in male patients presenting with atypical motor neurone disease. 相似文献
9.
J F Tomera K D Friend S P Kukulka K Lilford 《The Journal of burn care & rehabilitation》1992,13(5):546-555
One systemic effect of burn trauma is skeletal muscle weakness. This is the result of changes in second messenger systems involving calcium (Ca2+). Kinetic analysis of Ca2+ from cellular compartments of skeletal muscle of mice that were subjected to small burn injury (20% body surface area) was performed. Muscles of the burn group showed an increased 45Ca2+ uptake maxima compared with those of time-matched control groups. Also, 45Ca2+ efflux analysis showed a lack of differentiation between electrically stimulated tissues and nonstimulated tissues that was easily observed in time-matched control groups. This lack of differentiation indicated changes in intracellular compartmentation. It can be speculated that burn trauma may have a regulatory role in the excitation-contraction coupling mechanism by altering myoplasmic levels of Ca2+ even before skeletal muscle dysfunction occurs. These findings suggest that agents capable of controlling myoplasmic Ca2+ levels may aid in alleviating chronic skeletal muscle dysfunction in patients with burns. 相似文献
10.
PJ Woll PhD MRCP R Pettengell PhD FRACP 《International journal of clinical practice》1997,51(2):111-115
SUMMARY The interferons are natural glycoproteins secreted in response to various stimuli, including viral infection. They have antiviral, antiproliferative and immunomodulatory effects on different target cell populations. Since recombinant human interferons have become available, they have been tested in a wide range of malignancies. They are well established in the treatment of hairy cell leukaemia, chronic myelogenous leukaemia and multiple myeloma. Although they have documented activity against lymphoma, melanoma, renal cell cancer and carcinoid tumours, their role in the treatment of these tumours is less clear. In the common solid tumours, such as lung cancer and colorectal cancer, the use of interferons remains experimental. Here we will summarise their practice applications in oncology, using randomised studies where available to establish their place in multi-modality treatment. We will not discuss their use as antiviral or immunomodulating agents in viral and autoimmune diseases, multiple sclerosis or after organ transplantation. 相似文献